Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer

BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seijong, Shin, Jung Kyong, Park, Yoonah, Huh, Jung Wook, Kim, Hee Cheol, Yun, Seong Hyeon, Lee, Woo Yong, Cho, Yong Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/
https://www.ncbi.nlm.nih.gov/pubmed/36353568
http://dx.doi.org/10.3389/fonc.2022.1018458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/
https://www.ncbi.nlm.nih.gov/pubmed/36353568
http://dx.doi.org/10.3389/fonc.2022.1018458

Ejemplares similares